Lisata Therapeutics (LSTA) Scheduled to Post Earnings on Thursday

Lisata Therapeutics (NASDAQ:LSTA) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Lisata Therapeutics to post earnings of ($0.73) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.20. On average, analysts expect Lisata Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Lisata Therapeutics Price Performance

Shares of LSTA opened at $2.75 on Wednesday. Lisata Therapeutics has a 1-year low of $1.95 and a 1-year high of $4.53. The stock has a market cap of $22.84 million, a price-to-earnings ratio of -1.07 and a beta of 1.08. The firm has a 50 day simple moving average of $3.00 and a 200-day simple moving average of $2.75.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Lisata Therapeutics in a report on Thursday, April 25th.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.